{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:57:10Z","timestamp":1740149830463,"version":"3.37.3"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005739","name":"Universidad Nacional Aut\u00f3noma de M\u00e9xico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005739","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Eosinophilic esophagitis (EoE) is a chronic, allergen-mediated, type-2 inflammatory disease with the potential to significantly impact an individual\u2019s quality of life. Conventional treatments often result in varied responses, prompting the need for novel therapeutic approaches. We present the case of a 19-year-old male with a medical history marked by eosinophilic esophagitis, severe atopic dermatitis (AD), asthma, and allergic rhinitis. Despite undergoing diverse topical and systemic interventions to address his AD and EoE, the patient\u2019s symptoms persisted. However, following the initiation of dupilumab therapy\u2014a dual IL-4 and IL-13 receptor antagonist\u2014the patient experienced a substantial reduction in his Eczema Area and Severity Index score. Notably, a marked improvement was also seen regarding his symptoms of eosinophilic esophagitis. A subsequent esophageal biopsy revealed a significant decrease in eosinophilic inflammation, consistent with established clinical and histologic remission criteria. These findings corroborate the patient\u2019s reported relief from symptoms. This case underscores the potential efficacy of dupilumab as a promising therapeutic agent in managing eosinophilic esophagitis. Dupilumab offers a dual benefit of alleviating symptoms and achieving histologic and clinical remission. This novel approach presents a noteworthy advancement in the treatment of EoE.<\/jats:p>","DOI":"10.1007\/s12328-024-02011-z","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T13:08:21Z","timestamp":1721826501000},"page":"803-808","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Sustained clinical and histopathological remission in a patient with eosinophilic esophagitis and type-2 comorbidities at 18\u00a0months after discontinuation of dupilumab"],"prefix":"10.1007","volume":"17","author":[{"given":"V\u00edctor","family":"Gonz\u00e1lez-Uribe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos Patricio Acosta","family":"Rodr\u00edguez-Bueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaira Selene","family":"Mojica-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Malag\u00f3n-Liceaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0078-9710","authenticated-orcid":false,"given":"Mart\u00edn Roberto","family":"Basile-Alvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"key":"2011_CR1","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1001\/jama.2021.14920","volume":"326","author":"A Muir","year":"2021","unstructured":"Muir A, Falk GW. Eosinophilic esophagitis: a review. JAMA. 2021;326:1310\u20138.","journal-title":"JAMA"},{"key":"2011_CR2","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1053\/j.gastro.2018.07.009","volume":"155","author":"ES Dellon","year":"2018","unstructured":"Dellon ES, Liacouras CA, Molina-Infante J, et al. Updated international consensus diagnostic criteria for eosinophilic esophagitis: Proceedings of the AGREE Conference. Gastroenterology. 2018;155:1022-1033.e10.","journal-title":"Gastroenterology"},{"key":"2011_CR3","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/jgh3.12059","volume":"2","author":"R Eke","year":"2018","unstructured":"Eke R, Li T, White A, Tariq T, et al. Systematic review of histological remission criteria in eosinophilic esophagitis. JGH Open. 2018;2:158\u201365.","journal-title":"JGH Open"},{"key":"2011_CR4","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1016\/j.cgh.2020.01.024","volume":"18","author":"EJ Laserna-Mendieta","year":"2020","unstructured":"Laserna-Mendieta EJ, Casabona S, Savarino E, et al. Efficacy of therapy for eosinophilic esophagitis in real-world practice. Clin Gastroenterol Hepatol. 2020;18:2903\u201311.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2011_CR5","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/all.14151","volume":"75","author":"A Le Floc'h","year":"2020","unstructured":"Le Floc\u2019h A, Allinne J, Nagashima K, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation. Allergy. 2020;75:1188\u2013204.","journal-title":"Allergy"},{"key":"2011_CR6","unstructured":"Food and Drug Administration. Dupixent (dupilumab). Highlights of prescribing information. 2022 (https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2022\/761055Orig1s040.pdf)"},{"key":"2011_CR7","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1056\/NEJMoa2205982","volume":"387","author":"ES Dellon","year":"2022","unstructured":"Dellon ES, Rothenberg ME, Collins MH, et al. Dupilumab in adults and adolescents with eosinophilic esophagitis. N Engl J Med. 2022;387:2317\u201330.","journal-title":"N Engl J Med"},{"key":"2011_CR8","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1080\/21645515.2019.1582403","volume":"15","author":"Q Thibodeaux","year":"2019","unstructured":"Thibodeaux Q, Smith MP, Ly K, et al. A review of dupilumab in the treatment of atopic diseases. Hum Vaccin Immunother. 2019;15:2129\u201339.","journal-title":"Hum Vaccin Immunother"},{"key":"2011_CR9","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.anai.2022.01.019","volume":"128","author":"BL Spergel","year":"2022","unstructured":"Spergel BL, Ruffner MA, Godwin BC, et al. Improvement in eosinophilic esophagitis when using dupilumab for other indications or compassionate use. Ann Allergy Asthma Immunol. 2022;128:589\u201393.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2011_CR10","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s12016-022-08934-0","volume":"62","author":"A Kychygina","year":"2022","unstructured":"Kychygina A, Cassagne M, Tauber M, et al. Dupilumab-associated adverse events during treatment of allergic diseases. Clin Rev Allergy Immunol. 2022;62:519\u201333.","journal-title":"Clin Rev Allergy Immunol"},{"key":"2011_CR11","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jdcr.2020.11.012","volume":"7","author":"M Ayasse","year":"2020","unstructured":"Ayasse M, Lockshin B, Do BK, et al. A case report of uveitis secondary to dupilumab treatment for atopic dermatitis. JAAD Case Rep. 2020;7:98\u20139.","journal-title":"JAAD Case Rep"},{"key":"2011_CR12","doi-asserted-by":"publisher","first-page":"873","DOI":"10.3390\/genes14040873","volume":"14","author":"Z Sahafnejad","year":"2023","unstructured":"Sahafnejad Z, Ramazi S, Allahverdi A. An update of epigenetic drugs for the treatment of cancers and brain diseases: a comprehensive review. Genes. 2023;14:873.","journal-title":"Genes"},{"key":"2011_CR13","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.4049\/jimmunol.158.3.1438","volume":"158","author":"DW MacGlashan Jr","year":"1997","unstructured":"MacGlashan DW Jr, Bochner BS, Adelman DC, et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol. 1997;158:1438\u201345.","journal-title":"J Immunol"},{"key":"2011_CR14","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.7150\/thno.18304","volume":"7","author":"M Metz","year":"2017","unstructured":"Metz M, Staubach P, Bauer A, et al. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of Fc\u03b5RI-positive cells in the skin. Theranostics. 2017;7:1266\u201376.","journal-title":"Theranostics"},{"key":"2011_CR15","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/S1473-3099(20)30653-8","volume":"21","author":"S Prentice","year":"2021","unstructured":"Prentice S, Nassanga B, Webb EL, et al. BCG-induced non-specific effects on heterologous infectious disease in Ugandan neonates: an investigator-blind randomised controlled trial. Lancet Infect Dis. 2021;21:993\u20131003.","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"2011_CR16","volume":"2022","author":"Z Hu","year":"2020","unstructured":"Hu Z, Lu SH, Lowrie DB, Fan XY. Trained immunity: a Yin-Yang balance. MedComm. 2020;2022(3): e121.","journal-title":"MedComm"},{"key":"2011_CR17","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/art.42415","volume":"75","author":"F Buttgereit","year":"2023","unstructured":"Buttgereit F, Aelion J, Rojkovich B, et al. Efficacy and safety of ABBV-3373, a novel anti-tumor necrosis factor glucocorticoid receptor modulator antibody-drug conjugate, in adults with moderate-to-severe rheumatoid arthritis despite methotrexate therapy: a randomized, double-blind, active-controlled proof-of-concept phase iia trial. Arthritis Rheumatol. 2023;75:879\u201389.","journal-title":"Arthritis Rheumatol"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-024-02011-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-024-02011-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-024-02011-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T13:19:29Z","timestamp":1727443169000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-024-02011-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["2011"],"URL":"https:\/\/doi.org\/10.1007\/s12328-024-02011-z","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"type":"print","value":"1865-7257"},{"type":"electronic","value":"1865-7265"}],"subject":[],"published":{"date-parts":[[2024,7,24]]},"assertion":[{"value":"12 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author(s) declared no potential conflicts of interest with to the research, authorship, and\/or publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent has been obtained from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}